92693-03-3

Usage

Uses

Used in Pharmaceutical Industry:
17(S)-HDoHE is used as an anti-inflammatory agent for its ability to inhibit the 5-lipoxygenase pathway, which plays a key role in mediating inflammation and is implicated in the pathogenesis of various neurodegenerative diseases.
Used in Neuroprotective Applications:
17(S)-HDoHE is used as a neuroprotective agent for its ability to promote cell survival and reduce oxidative stress in neuronal cells, highlighting its potential therapeutic value in the treatment of conditions such as Alzheimer's disease and Parkinson's disease.
Used in Diagnostic Applications:
17(S)-HDoHE is used as a potential biomarker for certain conditions due to its altered levels in various disease states, which may open up new avenues for diagnostic and therapeutic intervention.
Used in Therapeutic Development:
17(S)-HDoHE is used as a promising compound for the development of novel therapeutics for inflammatory and neurodegenerative disorders, given its multifaceted beneficial effects on neuronal health and disease pathogenesis.

Upstream product

• 6217-54-5 docosahexaenoic acid 
• 123673-33-6 17(S)-hydroperoxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid 

Downstream Products

• 1233715-28-0 17-oxo-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid 
• 90780-52-2 (±)-(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoic acid 

Relevant academic research and scientific papers

First total synthesis of the anti-inflammatory and pro-resolving lipid mediator 16(R),17(S)-diHDHA

The first total synthesis of the anti-inflammatory and pro-resolving lipid mediator 16(R),17(S)-diHDHA, derived from docosahexaenoic acid (DHA), and its 16-epimer have been achieved. Two synthetic approaches are described for the synthesis of 16(R),17(S)-diHDHA. The first strategy started from DHA and used an enzymatic reaction, a vanadium catalyzed allylic epoxidation and a base-promoted epoxide isomerization. The second approach utilized a chiral pool strategy starting from 2-deoxy-D-ribose to establish the chiral centers; Wittig reactions, mild acetonide cleavage and ester hydrolysis were the key steps in the synthesis.

RESOLVINS: BIOTEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS

The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

Production of hydroxy unsaturated fatty acids using crude lipoxygenase obtained from infected rice plants

In order to explore the oxidation mode of lipoxygenase (LOX) obtained from infected rice plants, typical unsaturated fatty acids (3-8) were treated with LOX and oxygen. It was observed that ω-10 and ω-6 positions of unsaturated fatty acids were oxidized predominantly in the cases of exotic ω-6 (4 and 5) and ω-3 (7 and 8) series, respectively. In the case of endogenous fatty acids (3 and 6), oxidation at ω-6 position predominated. All the allylic alcohols obtained by reduction of the oxidation products with NaBH4 possess S-configuration.